433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial...

by Min Yi, Celeste Lebbe, Parminder Singh, Omid Hamid, Jason Chesney, Igor Puzanov, Mohammed Milhem, Merrick Ross, Janice Mehnert, Theodore Logan, Philip Friedlander, Frances Collichio, Claus Garbe, John Glaspy, Axel Hauschild, Wendy Snyder
Published 2020-11-01